Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1061 to 1070 of 2733 total matches.
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 09, 2009 (Issue 1307)
, glatiramer acetate, mitoxantrone and, more recently,
natalizumab.
1-3
The development of progressive ...
Alemtuzumab (Campath), a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Benzyl Alcohol Lotion for Head Lice
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
-2769
Table 1. Medications for Head Lice
Drug Ovicidal Resistance Dosage ...
The FDA has approved benzyl alcohol lotion, 5% (Ulesfia Lotion - Sciele) for treatment of head lice in patients ≥6 months old. The active ingredient is 5% benzyl alcohol; the vehicle is 5% mineral oil.
Aptensio XR - Another Long-Acting Methylphenidate for ADHD
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
of Aptensio XR
for 2-4 weeks, followed by crossover treatment for 1
week each with placebo and the new ...
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Alirocumab (Praluent) to Lower LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
of ≥50%, for patients with clinical
atherosclerotic cardiovascular disease.1 The National
Lipid ...
The FDA has approved the subcutaneously injected
PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor alirocumab (Praluent – Sanofi/Regeneron)
as an adjunct to diet and maximally tolerated
statin therapy for adults with heterozygous familial
hypercholesterolemia (HeFH) or clinical atherosclerotic
cardiovascular disease who require additional lowering
of LDL-cholesterol (LDL-C). It was not approved for
general use in statin-intolerant patients. Alirocumab
is the first PCSK9 inhibitor to be approved in the US.
Evolocumab (Repatha – Amgen), another PCSK9
inhibitor, was...
Lerodalcibep (Lerochol) for Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • May 11, 2026 (Issue 1754)
(see Table 3).1
Table 1. Pharmacology
Class Proprotein convertase subtilisin/kexin type 9
(PCSK9 ...
The FDA has approved lerodalcibep (Lerochol – Lib
Therapeutics), a subcutaneously injected proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitor, to
reduce low-density lipoprotein cholesterol (LDL-C) in adults
with hypercholesterolemia, including heterozygous familial
hypercholesterolemia (HeFH). Lerodalcibep is the fourth
subcutaneously injected PCSK9-directed therapy to be
approved in the US; the monoclonal antibodies alirocumab
(Praluent) and evolocumab (Repatha) and the small interfering
RNA inclisiran (Leqvio) were approved earlier (see Table...
Med Lett Drugs Ther. 2026 May 11;68(1754):73-5 doi:10.58347/tml.2026.1754a | Show Introduction Hide Introduction
Topical Terbinafine for Tinea Infections
The Medical Letter on Drugs and Therapeutics • Aug 20, 1993 (Issue 903)
FOR
ONLINE USERS
TOPICAL TERBINAFINE FOR TINEA INFECTIONS
Terbinafine 1% cream (Lamisil − Sandoz ...
Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of tinea pedis, tinea cruris, and tinea corporis infections. An oral formulation is available in Europe and is under investigation here.
Dutasteride (Avodart) for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • Dec 23, 2002 (Issue 1146)
-reductase inhibitors
usually take months to have a noticeable effect. The alpha
1
blockers terazosin ...
Dutasteride (Avodart - GlaxoSmithKline) is now available in the US for oral treatment of benign prostatic hyperplasia (BPH). It is similar to finasteride (Proscar - Merck), which has been marketed for this indication since 1992 and also, since 1998, for alopecia (Propecia - Medical Letter 1998; 40:25).
Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006 (Issue 1228)
, asparaginase,
cyclophosphamide and cytarabine.
1
The prognosis after
relapse is generally poor.
MECHANISM ...
Nelarabine (Arranon - GlaxoSmithKline), a prodrug of the deoxyguanosine analog 9-β-D-arabinofuranosylguanine (ara-G), has been approved by the FDA for treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.
Mumps Outbreak Recommendations
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006 (Issue 1236)
has spread.
1
About 40% of the cases
have been in people 18-25 years old, many of whom
are college ...
A large mumps outbreak that began in Iowa in December 2005 has spread. About 40% of the cases have been in people 18-25 years old, many of whom are college students and had been vaccinated against the disease.
Advertisements for TNF Inhibitors
The Medical Letter on Drugs and Therapeutics • Nov 17, 2008 (Issue 1299)
that their long-term safety is far from established.
1. CL Leonardi et al. Etanercept as monotherapy in patients ...
Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis (www.yahoo.com).
